TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022
TRACON Pharmaceuticals (Nasdaq: TCON) will announce its Q3 2022 financial results on November 14, 2022, after U.S. markets close. A conference call is scheduled for 4:30 PM ET to discuss these results and corporate activities. The company specializes in developing targeted cancer therapeutics and operates independently of contract research organizations (CROs). The pipeline includes several promising candidates, such as Envafolimab for sarcoma and YH001, a CTLA-4 antibody in Phase 1. TRACON aims to establish partnerships for further development.
- Pipeline includes promising candidates: Envafolimab in pivotal ENVASARC trial and YH001 in Phase 1.
- Cost-efficient, CRO-independent development platform positions TRACON favorably for partnerships.
- None.
SAN DIEGO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Monday, November 14, 2022. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results.
| Date: | November 14, 2022 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Conference Call: | In order to participate in the live conference call, you must register in advance here: registration link. After registering, you will receive an email with dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast. |
| Webcast: | https://traconpharma.gcs-web.com/events-and-presentations/upcoming-events |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Charles Theuer | Brian Ritchie |
| Chief Executive Officer | LifeSci Advisors LLC |
| (858) 550-0780 | (212) 915-2578 |
| ctheuer@traconpharma.com | britchie@lifesciadvisors.com |
FAQ
What are the upcoming financial results for TRACON Pharmaceuticals?
What time is the TRACON Pharmaceuticals conference call?
What is TRACON Pharmaceuticals' focus in the biopharmaceutical industry?
What is the significance of the ENVASARC trial for TRACON?
